Just think about multiple myeloma and the impact of DARZALEX, CARVYKTI, TECVAYLI and TALVEY. Think about heart recovery and the impact of Abiomed's Impella heart pumps and the promise of V-Waves ...

The 94-patient cohort had an overall response rate (ORR) of 78% across a range of doses of talquetamab (Talvey) and teclistamab (Tecvayli), including 80% of patients treated with the recommended ...

Jan. 14 (UPI) --The U.S. Food and Drug Administration hopes "front-of-package" labeling will better improve the American population's health, the FDA announced. "Food should be a vehicle for ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

and Talvey, whose revenue numbers are yet to be broken out. Also mentioned were depression med Spravato - $1bn revenues in 2024, up 56%, Tremfya, expected to be a long-term replacement for Stelara ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson Joseph Wolk; Chief Financial Officer, Executive Vice President; Johnson & Johnson Jennifer Taubert; Executive Vice ...

J&J will also be looking for growth from newer medicines including Tecvayli and Talvey. Outside of oncology, J&J’s depression treatment Spravato brought in sales of $1.1 billion for the year ...

Get Instant Summarized Text (Gist) Talquetamab combined with teclistamab shows a high response rate in patients with relapsed or refractory multiple myeloma, with 80% responding to the recommended ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson Joseph Wolk; Chief Financial Officer, Executive Vice President; Johnson & Johnson Jennifer Taubert; Executive Vice ...